Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab + Chemotherapy in First-line Advanced NSCLC
NCT03409614Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 18
01
Overview
A Phase 3 trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Regeneron Pharmaceuticals. Started Mar 2018; status: completed.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03409614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03409614.